<DOC>
	<DOCNO>NCT00191789</DOCNO>
	<brief_summary>Gemcitabine anthracycline combination show encouraging activity neoadjuvant chemotherapy locally advance breast cancer . An addition sequential gemcitabine cisplatin , also highly active combination indication , may result improvement pathological response overall survival . Patients operable breast cancer treat neoadjuvant setting gemcitabine plus doxorubicin , follow gemcitabine plus cisplatin .</brief_summary>
	<brief_title>Neoadjuvant Sequential Administration Two Gemcitabine Combinations Operable Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Diagnosis breast carcinoma No previous chemotherapy , bidimensionally measurable locally advanced disease Adequate performance status ( Karnofsky Performance Status [ KPS ] great equal 70 ) , bone marrow reserve , hepatic , cardiac renal function . Inflammatory breast cancer Pregnancy Breastfeeding Serious concomitant disorder infection Previous cancer within last 5 year second primary malignancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>